The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Are European patents obstacles to Swedish cancer research?

På svenska

Author

Editor

  • Susanne Lundin
  • Lynn Åkesson

Summary, in English

Professor Håkan Olsson, Lund has addressed the problems caused by patenting in the field of biotechnology. His article was triggered by patent protection acquired by the American company Myriad Genetics. According to HO, Myriad requires that analyses of blood to trace the occurrence of these genes should be carried out in the company’s American laboratories, at a significant cost. Profit is infringing on the freedom of academic research and HO therefore asks:

• Is it reasonable to patent “inventions” in gene technology?

• Can patent protection be allowed to impede urgent, serious and non-commercial research?

• Can patent protection be circumvented by coercive measures?

• Should patentees be able to monopolize analytical work in medical care?

In this article I examine the system from a legal perspective. Are there solutions to the problems encountered by a researching physician, or must the rules be changed?

Department/s

Publishing year

2002

Language

English

Pages

52-71

Publication/Series

Gene technology and economy

Document type

Book chapter

Publisher

Nordic Academic Press

Topic

  • Law

Keywords

  • civilrätt: immaterialrätt
  • private law: intellectual property law
  • biotechnology
  • patenting
  • research exemption.

Status

Published

ISBN/ISSN/Other

  • ISBN: 9189116259